Clinical Trial: ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers

U.S., Jan. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07314268) titled 'ATTR Amyloid Cardiomyopathy: Characterization of Extracellular Vesicles as Potential Disease Stratifiers and Prognostic Biomarkers' on Nov. 25, 2025.

Brief Summary: This study explores whether extracellular vesicles (EVs) tiny particles released into the bloodstream by cells can serve as early and minimally invasive biomarkers for transthyretin amyloid cardiomyopathy (ATTR-CM). Because ATTR-CM is often diagnosed only after significant heart damage has occurred, there is an urgent need for earlier detection methods.

The study will enroll individuals with different clinical presentations of transthyretin amyloidosis, along with health...